Navigation Links
MIGENIX Corporate Update and Requisition of Special Meeting
Date:7/8/2008

Board and Management Focused on Near-Term Milestones and Maintain

Commitment to Strategy

VANCOUVER and SAN DIEGO, July 8 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, has received a requisition for a special meeting of shareholders for the purpose of acquiring control of MIGENIX's board of directors (see "Requisition of Shareholder Meeting"). Management and the board maintain their commitment to all MIGENIX shareholders to create value based on our existing pharmaceutical product development strategy and are continuing to work diligently on opportunities to create value (see "Program Update").

Jim DeMesa, M.D., President and CEO of MIGENIX stated, "Since announcing our strategic plan in 2002, management has maintained a focus on achieving the objectives outlined in that plan to build long-term value for our shareholders. Familiar to all in the biotech space, drug development is a long, risky process with many setbacks. We have been navigating that course and are now on the verge of some of the results of our strategy. Importantly, we are very close to a pivotal milestone for our latest-stage product candidate - Omigard(TM), with Phase III clinical results expected before the end of the calendar year (see "Program Update" below). Armed with positive results from this study, our partner in this program, Cadence Pharmaceuticals, plans to submit a New Drug Application (NDA) for marketing approval of Omigard(TM) in the United States in the first half of calendar 2009 - which is a significant event for any biotech or pharmaceutical company. Also, with positive Phase III results, we expect to partner the additional commercial rights to Omigard to maximize revenue to the Company for further value creation. This is in addition to the potential US$27MM in milestone payments under our agreement with Cadence and double digit royalty revenue on net sale
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
8. MIGENIX releases CEO message #22
9. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
11. MIGENIX Appoints Pieter Dorsman to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2014)... September 27, 2014 Synedgen announced ... Innovation Research (SBIR) Phase I contract from the ... of Health (NIH) to demonstrate proof-of-concept activity of ... that causes painful tissue damage to the lining ... , With this award, Synedgen will complete efficacy ...
(Date:9/26/2014)... , Sept. 26, 2014 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic stem ... Company will hold its 2014 annual general meeting of shareholders at ... of China Tower, 1 Garden Road, Central, Hong Kong ... 2014 (8:00 a.m. U.S. Eastern Time on December 11, 2014). ...
(Date:9/26/2014)... Foster City, CA (PRWEB) September 26, 2014 ... molecular mechanisms occurring in the cell for the regulation ... physical, chemical and biochemical interactions between genes and with ... helps us in innovation of new and novel therapeutic ... the various lethal syndromes. , On this occasion, Dr. ...
(Date:9/26/2014)... 2014 “Inflamax’s Clinical Data Management group ... events like this allows us to support our group ... says Derek Johnson, Director of Data Management at Inflamax. ... all of our Clinical Data Managers have been certified ... are committed to offering only the best services to ...
Breaking Biology Technology:Synedgen Awarded National Cancer Institute Funding for Promising New Treatment for Medical Radiation-induced Bowel Injury 2China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 11, 2014 2Understanding Genetics and Molecular Biology to Avert Dreadful Medical Challenges during Open Access Week 2Understanding Genetics and Molecular Biology to Avert Dreadful Medical Challenges during Open Access Week 3
... New York, NY - One certain consequence of the ... cleaning. The first bigwig out the door is Dr. ... and development operations. Today, Celltech, one of Europe's biggest ... , ,"You will see that the entire senior management ...
... Fiserv AIS is a provider ... The configurability of the system allows business users ... intervention, so expensive technical resources are conserved. The ... solutions enables companies to automate customer communication, ...
... you brought Bill Gates to his tender knees. Oh, yes, you ... worm writer, you!" It echoed among the buildings, all but drowning ... the whimpers you could almost hear Billy saying it: "I will, ... my software."* , ,Wow, if only the U.S. antitrust ...
Cached Biology Technology:Pfizer-Pharmacia Fallout Gives Celltech A CEO 2Open Letter: Blasted Worm 2Open Letter: Blasted Worm 3
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may ... week in mBio , the online open-access journal of ... from the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal ... ramosum gained weight when fed a high-fat diet. Mice ... obese even when consuming a high-fat diet, and mice that ...
(Date:9/29/2014)... exposure to tar tended to be lower for smokers ... exposure to nicotine tended to be lower. , Slim ... several countries around the world. Previous studies have shown ... smoke of these cigarettes are lower than those in ... the smoke are not necessarily linked to a reduced ...
(Date:9/29/2014)... 29, 2014 -- Plants have a symbiotic relationship ... pants extract nutrients and defend against invaders ... fruits and vegetables. Now, scientist have discovered that ... seeds; thus ensuring that sprouting plants are colonized ... of Notre Dame, presented their findings today at ...
Breaking Biology News(10 mins):Gut bacteria promote obesity in mice 2Slim cigarette smokers not exposed to more harmful chemicals 2Plants prepackage beneficial microbes in their seeds 2
... More Likely to Have Sleep Disorder , (#1119044, Wednesday, October ... movements when sleeping, which may vary in intensity, may be ... study of 100 patients with PMLD, researchers from Toledo, Ohio ... who were left-handed. Of the 84 right-handed and 16 left-handed ...
... Thomas Jefferson High School for Science and Technology is ... the Journal of Visualized Experiments . Though ... in PubMed and MEDLINE, has video articles showing basic experimental ... out of Ivy League schools -- not the level of ...
... identifying ideal drug combinations from billions of others which ... in Nature Chemical Biology , could be the ... to combat severe diseases and conditions. Most non-infectious ... by inflammation, which is the body,s natural defence mechanism. ...
Cached Biology News:CHEST 2011: Embargoed studies highlight new sleep disorder research 2CHEST 2011: Embargoed studies highlight new sleep disorder research 3Manchester's 'first step' to perfect drug combinations 2
... xi 2-D system runs both gel dimensions in the ... can be separated in a single run using the ... in much the same manner as the slab gel ... slab gels may be cast in the casting stand. ...
... Application Series are a line of ... provide fast and reliable automated solutions ... robust "automation-friendly" building blocks, Caliper has ... less than conventional approaches, take up ...
... 2-Methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidine-4-one White solid. ... A brain-permeable and water soluble pyrimidinone compound ... + -competitive inhibitor of PARP (IC 50 ... for rhPARP1 and rmPARP2, respectively) with little ...
...
Biology Products: